UPTRAVI 400 MCG 60 F.C.TABS

INDICATION UPTRAVI� (selexipag) is indicated for the treatment of pulmonary arterial hypertension (PAH WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH. Effectiveness was established in a long-term study in PAH patients with WHO Functional Class II-III symptoms. Patients had idiopathic and heritable PAH (58%) PAH associated with connective tissue disease (29%) and PAH associated with congenital heart disease with repaired shunts (10%).